Literature DB >> 35947068

Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats.

Adriaan W Bruijnzeel1,2, Azin Behnood-Rod1, Wendi Malphurs3, Ranjithkumar Chellian1, Robert M Caudle4, Marcelo Febo1,2, Barry Setlow1,2, John K Neubert3.   

Abstract

The prescription opioid oxycodone is widely used for the treatment of pain in humans. Oxycodone misuse is more common among people with an anxiety disorder than those without one. Therefore, oxycodone might be misused for its anxiolytic properties. We investigated if oxycodone affects anxiety-like behavior in adult male and female rats. The rats were treated with oxycodone (0.178, 0.32, 0.56, or 1 mg/kg), and anxiety-like behavior was investigated in the elevated plus-maze test. Immediately after the elevated plus-maze test, a small open field test was conducted to determine the effects of oxycodone on locomotor activity. In the elevated plus-maze test, oxycodone increased the percentage of time spent on the open arms, the percentage of open arm entries, time on the open arms, open arm entries, and the distance traveled. The males treated with vehicle had a lower percentage of open arm entries than the females treated with vehicle, and oxycodone treatment led to a greater increase in the percentage of open arm entries in the males than females. Furthermore, the females spent more time on the open arms, made more open arm entries, spent less time in the closed arms, and traveled a greater distance than the males. In the small open field test, treatment with oxycodone did not affect locomotor activity or rearing. Sex differences were observed; the females traveled a greater distance and displayed more rearing than the males. In conclusion, oxycodone decreases anxiety-like behavior in rats, and oxycodone has a greater anxiolytic-like effect in males than females.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35947068      PMCID: PMC9373716          DOI: 10.1097/FBP.0000000000000690

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.277


  54 in total

1.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

2.  The age-dependent effect of pre-pubertal castration on anxiety-like behaviour in male rats.

Authors:  Emese Renczés; Veronika Borbélyová; Lenka Keresztesová; Daniela Ostatníková; Peter Celec; Július Hodosy
Journal:  Andrologia       Date:  2020-05-20       Impact factor: 2.775

3.  A lack of tolerance to the anxiolytic effects of diazepam on the plus-maze: comparison of male and female rats.

Authors:  H Stock; C Foradori; K Ford; M A Wilson
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

4.  Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors.

Authors:  P Maguire; N Tsai; J Kamal; C Cometta-Morini; C Upton; G Loew
Journal:  Eur J Pharmacol       Date:  1992-03-24       Impact factor: 4.432

5.  Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Zhihui Yang; Marcelo Febo; Zhiying Shan; Kevin K W Wang; Adriaan W Bruijnzeel
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-22       Impact factor: 4.600

6.  Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice.

Authors:  Natalia N Kudryavtseva; Mirjam A F M Gerrits; Damira F Avgustinovich; Michael V Tenditnik; Jan M Van Ree
Journal:  Peptides       Date:  2004-08       Impact factor: 3.750

7.  Estrogen-dependent alterations in D2/D3-induced G protein activation in cocaine-sensitized female rats.

Authors:  Marcelo Febo; Loida A González-Rodríguez; David E Capó-Ramos; Naggai Y González-Segarra; Annabell C Segarra
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

8.  Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice.

Authors:  Mansuo L Hayashi; B S Shankaranarayana Rao; Jin-Soo Seo; Han-Saem Choi; Bridget M Dolan; Se-Young Choi; Sumantra Chattarji; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

Review 9.  Oxycodone: a review of its use in the management of pain.

Authors:  Julia Riley; Elon Eisenberg; Gerhard Müller-Schwefe; Asbjørn M Drewes; Lars Arendt-Nielsen
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

10.  Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Elizabeth Crane; Jinhee Lee; Christopher M Jones
Journal:  Ann Intern Med       Date:  2017-08-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.